Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-13 pm EDT 		5-day change 1st Jan Change
129.3 USD -0.59% Intraday chart for Merck & Co., Inc. +1.35% +18.59%
May. 13 Merck: phase 3 trial in melanoma halted CF
May. 13 Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study DJ

Business Summary

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:

- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;

- sale of vaccines (18%);

- sale of animal health products (9.4%);

- other (2.9%).

Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Number of employees: 71,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
89.1 %
52,005 87.7 % 53,583 89.1 % +3.03%
Animal Health
9.4 %
5,550 9.4 % 5,625 9.4 % +1.35%
Other
1.5 %
1,728 2.9 % 907 1.5 % -47.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
47.4 %
27,206 45.9 % 28,480 47.4 % +4.68%
Europe, Middle East and Africa
22.0 %
14,493 24.4 % 13,254 22.0 % -8.55%
China
11.3 %
5,191 8.8 % 6,802 11.3 % +31.03%
Asia Pacific
5.4 %
3,614 6.1 % 3,225 5.4 % -10.76%
Japan
5.3 %
3,629 6.1 % 3,164 5.3 % -12.81%
Latin America
5.1 %
2,582 4.4 % 3,086 5.1 % +19.52%
Other
3.5 %
2,568 4.3 % 2,104 3.5 % -18.07%

Managers

Managers TitleAgeSince
Robert Davis CEO
 Chief Executive Officer 57 14-03-31
Caroline Litchfield DFI
 Director of Finance/CFO 55 89-12-31
Dave Williams CTO
 Chief Tech/Sci/R&D Officer 55 20-07-31
Joseph Romanelli IRC
 Investor Relations Contact 50 95-12-31
Peter Dannenbaum IRC
 Investor Relations Contact - 17-06-30
Andre Musto PRN
 Corporate Officer/Principal - 14-06-30
Brooke Hinkson PRN
 Corporate Officer/Principal - 15-07-31
Carol Bowden PRN
 Corporate Officer/Principal - 14-03-31
Dalton Smart AUD
 Comptroller/Controller/Auditor 58 09-10-31
James Matteucci PRN
 Corporate Officer/Principal - 02-12-31

Members of the board

Members of the board TitleAgeSince
Tom Glocer BRD
 Director/Board Member 63 07-11-26
Pamela Craig BRD
 Director/Board Member 67 15-08-31
Inge Thulin BRD
 Director/Board Member 69 18-02-28
Patricia Russo BRD
 Director/Board Member 71 95-08-31
Peter Wendell BRD
 Director/Board Member 73 03-09-22
Risa Lavizzo-Mourey BRD
 Director/Board Member 69 20-05-25
Robert Davis CEO
 Chief Executive Officer 57 14-03-31
Douglas Baker BRD
 Director/Board Member 65 22-05-23
Stephen Mayo BRD
 Director/Board Member 62 21-03-14
Kathy Warden BRD
 Director/Board Member 52 20-03-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,577,208,962 2,531,406,448 ( 70.76 %) 1,044,402,655 ( 29.20 %) 70.76 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.605 %
243,269,899 9.605 % 31 800 M $
BlackRock Advisors LLC
6.178 %
156,460,386 6.178 % 20 453 M $
STATE STREET CORPORATION
4.614 %
116,865,977 4.614 % 15 277 M $
Wellington Management Co. LLP
3.380 %
85,595,999 3.380 % 11 189 M $
Geode Capital Management LLC
2.189 %
55,428,245 2.189 % 7 246 M $
BlackRock Life Ltd.
1.703 %
43,121,867 1.703 % 5 637 M $
Fidelity Management & Research Co. LLC
1.688 %
42,749,954 1.688 % 5 588 M $
Eaton Vance Management
1.585 %
40,129,825 1.585 % 5 246 M $
Merrill Lynch International
1.562 %
39,559,512 1.562 % 5 171 M $
T. Rowe Price International Ltd.
1.188 %
30,087,217 1.188 % 3 933 M $
NameEquities%Valuation
Caixa DTVM SA
0.001468 %
297,420 0.001468 % 5 M $
BB Gestão de Recursos DTVM SA
0.000733 %
148,500 0.000733 % 2 M $
Safra Asset Management Ltda.
0.000363 %
73,600 0.000363 % 1 M $
Bram Bradesco Asset Management S/A DTVM
0.000231 %
46,754 0.000231 % 754 833 $
XP Allocation Asset Management Ltda.
0.000093 %
18,843 0.000093 % 304 216 $

Holdings

NameEquities%Valuation
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
10.62%
 13,443,693 10.62% 289,287,301 $
ENTRADA THERAPEUTICS, INC.
5.17%
 1,739,768 5.17% 21,503,532 $
XILIO THERAPEUTICS, INC.
4.02%
 1,483,414 4.02% 1,498,248 $
EVAXION BIOTECH A/S
12.13%
 2,297,884 12.13% 946,728 $

Company contact information

Merck & Co., Inc.

126 East Lincoln Avenue

07065, Rahway

+908 740 4000

http://www.merck.com
address Merck & Co., Inc.(MRK)

Group companies

NameCategory and Sector
FULFORD (INDIA) LIMITED
Pharmaceuticals: Major
Organon (India) Pvt Ltd.
Logo Organon (India) Pvt Ltd.

Organon (India) Pvt Ltd.

Pharmaceuticals: MajorHealth Technology

Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India.

Pharmaceuticals: Major
Dashtag
Logo Dashtag

Dashtag

Financial ConglomeratesFinance

Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK.

Financial Conglomerates
MSD Sharp & Dohme GmbH
Logo MSD Sharp & Dohme GmbH

MSD Sharp & Dohme GmbH

Pharmaceuticals: MajorHealth Technology

Part of Merck & Co., Inc., MSD Sharp & Dohme GmbH develops and manufactures pharmaceutical products. The private company is based in Haar, Germany. The German company was founded in 1891. Chantal Friebertshäuser has been the CEO of the company since 2007.

Pharmaceuticals: Major
Merck Holdings, Inc.
Merck Sharp & Dohme Corp.
Logo Merck Sharp & Dohme Corp.

Merck Sharp & Dohme Corp.

Pharmaceuticals: MajorHealth Technology

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Pharmaceuticals: Major
Intervet India Pvt Ltd.
Essex Chemie AG
Merck Sharp & Dohme Finance Europe Ltd.
Logo Merck Sharp & Dohme Finance Europe Ltd.

Merck Sharp & Dohme Finance Europe Ltd.

Miscellaneous Commercial ServicesCommercial Services

Founded in 1993, Merck Sharp & Dohme Finance Europe Ltd. is a British company that provides business support services. Part of Merck & Co., Inc., the private company is based in Hoddesdon, UK.

Miscellaneous Commercial Services

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Merck & Co., Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.3 USD
Average target price
141.6 USD
Spread / Average Target
+9.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 327B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 364B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
NOVARTIS AG Stock Novartis AG
+9.66% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 203B
AMGEN INC. Stock Amgen Inc.
+7.09% 165B
PFIZER, INC. Stock Pfizer, Inc.
-1.22% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Company Merck & Co., Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW